Abbott Laboratories (ABT) - Get Abbott Laboratories Report is slated to unveil its second-quarter results on Thursday, July 20, as the healthcare company works on completing its acquisition of Alere Inc. (ALR) .
In a July 13 note, BMO Capital Markets Inc. analyst Joanne Wuensch said she anticipates the second quarter to be at least in line with consensus estimates and expects updates from the Abbott Park, Ill.-based company on its integration of St. Jude Medical Inc. and its pending acquisition of Alere.
Analysts have forecast adjusted earnings per share of 61 cents on revenue of $6.6 billion, according to Bloomberg.
Abbott completed its $33 billion deal for St. Jude, a maker of heart-failure devices and technology, in January.
Abbott expects to close its acquisition of Alere by the third quarter. In April, Abbott and Alere agreed to shave $500 million off the deal's price tag, ending litigation between the two companies. Under the amended agreement, Abbott will pay $51 per Alere share, or $5.3 billion in equity value. In their original merger agreement, announced Feb. 1, 2016, Abbott agreed to pay $56 per share, an equity value of $5.8 billion, with an enterprise value of $7.9 billion.
On July 7, Alere said its shareholders have voted to approve the amended merger. Abbott on July 17 said it has commenced a tender offer to buy all outstanding shares of Series B convertible perpetual preferred stock of Alere. Also on July 17 came news that Alere's Triage assets were being sold to Quidel Corp. (QDEL) - Get Quidel Corporation Report to secure antitrust approvals for the Abbott-Alere deal. Quidel agreed to buy the assets for $400 million plus $40 million in contingent consideration.
Among the other topics to look out for on Abbott's earnings call, BMO's Wuensch wrote, is an update on the company's product pipeline, "including Libre in Europe and expectations for a 2H17E U.S. launch of the consumer version of Freestyle Libre, the 4Q17E FDA approval for MRI-safe labeling for the legacy St. Jude Medical ICDs and CRT-Ds portfolio, and the Absorb bioresorbable stent, which faces an FDA review following lackluster data from the ABSORB III trial."
Other topics include Abbott's Chinese nutritional franchise and the Alinity suite of diagnostic tools, Wuensch wrote.
Shares of Abbott were trading at $49.35 on Wednesday, up 1.3%. The stock is up 28.5% year-to-date.
Worried about how to finance your golden years? Register here to watch a free webinar in which TheStreet's Jim Cramer talks with Ken Fisher, founder of Fisher Investments, about the market trends shaping retirement planning today
More of What's Trending on TheStreet:
- Carly Fiorina's Advice to Young Women: Don't Let Other People Define You
- 10 Reasons Working From Home Might Be the Wave of the Future
- T-Mobile's John Legere Is Inarguably One of the More Colorful CEOs on Twitter
- Restaurant Brands 36-Year Old CEO Discusses the Burger King Whopper, Amazon's Jeff Bezos
- Amazon Faces a Potential Existential Threat That Could Hammer Its Shares, Doug Kass Reveals
- Game of Thrones Has Become Huge -- Here's How You Can Quickly Tell